Journal of Immunology

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

Retrieved on: 
Tuesday, April 2, 2024
Research, Journal of Immunology, Translational research, Myelocyte, Collaboration, Neutrophil, Vaccine

Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the publication of novel data in the peer-reviewed Journal of Immunology (1) on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy.

Key Points: 
  • Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the publication of novel data in the peer-reviewed Journal of Immunology (1) on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy.
  • In the new publication, the collaborative research work confirmed and reinforced the potential of CLEC-1 as a novel myeloid immune checkpoint regulating acute immune responses.
  • Dr Elise Chiffoleau, INSERM scientist, said: “We are very pleased to have these novel research data published in “Journal of Immunology”, an internationally recognized scientific journal.
  • Our collaborative work shows, for the first time, that CLEC-1 acts as an immune checkpoint for the control of acute immune responses in the context of sterile inflammation.

Key protein linked to immune disorders

Retrieved on: 
Thursday, March 14, 2024
Health, B cell, Cell, Communication, Multiple sclerosis, Inflammation, Journal, Research, DSM-IV codes, Bacteria, Virus, Hokkaido University, Protein, Asthma, Cytokine, Infection, Immune system, Journal of Immunology, Antigen, Vaccine

SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

Key Points: 
  • SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells.
  • Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.
  • "Our findings provide valuable insights into the molecular mechanisms underlying T cell activation and the development of immune disorders," says Tadashi Matsuda, a Hokkaido University professor who led the study.
  • Future research can build on this work by exploring the potential of STAP-1 as a therapeutic target for treating immune-related disorders.

Key protein linked to immune disorders

Retrieved on: 
Thursday, March 14, 2024
Health, B cell, Cell, Communication, Multiple sclerosis, Inflammation, Journal, Research, DSM-IV codes, Bacteria, Virus, Hokkaido University, Protein, Asthma, Cytokine, Infection, Immune system, Journal of Immunology, Antigen, Vaccine

SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

Key Points: 
  • SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells.
  • Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.
  • "Our findings provide valuable insights into the molecular mechanisms underlying T cell activation and the development of immune disorders," says Tadashi Matsuda, a Hokkaido University professor who led the study.
  • Future research can build on this work by exploring the potential of STAP-1 as a therapeutic target for treating immune-related disorders.

OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook

Retrieved on: 
Friday, January 19, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Journal of Immunology, HCC, ICI, CD47, Cancer, EMA, Journal, Pembrolizumab, IL-7, Kidney transplantation, Acute lymphoblastic leukemia, Annals of Oncology, Nivolumab, Fortification, ESMO, Hepatocellular carcinoma, Safety, Inflammation, Ulcerative colitis, Patent, Ovarian cancer, Failure, Survival, Immunotherapy, Boehringer Ingelheim, Committee, Myelocyte, Oncology, Patient, European Medicines Agency, ALL, Partnership, Lung cancer, Head, Pancreatic cancer, Phase II, FDA, Clinical trial, FOLFIRI, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.
  • Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “The Company has a broad portfolio of 5 products in clinical development with significant advances reached in 2023 and key milestones expected in 2024.
  • Our shared ambition at OSE is to create value by leading our two advanced assets in phase 2 and phase 3 to a clinical inflection point allowing a structuring agreement.
  • Thus, from Q1 2024, the Company could have validated doses and therapeutic regimens to consider the implementation of possible other clinical trials.

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Wednesday, August 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Therapy, Progression-free survival, Itolizumab, G&A, NK, Journal of Immunology, Alopecia areata, Retirement, Investment, Lupus nephritis, Ono Pharmaceutical, European Society for Primary Immunodeficiencies, R, SVP, Pharmaceutical industry, Bank

Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2023 and provided corporate and clinical development updates.

Key Points: 
  • Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2023 and provided corporate and clinical development updates.
  • Research and development (R&D) expenses for the second quarter of 2023 were $9.6 million, compared with $9.5 million for the same period in 2022.
  • General and administrative (G&A) expenses for the second quarter of 2023 were $3.1 million, compared with $4.1 million for the same period in 2022.
  • Net cash used in financing activities in the second quarter of 2023 was $7.6 million, which was driven by the prepayment and retirement of our former debt facility.

EQS-News: Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases

Retrieved on: 
Thursday, July 6, 2023
Asos, Asthma, Central nervous system, University, Chronic kidney disease, Arthritis, Fever, NOMID, FCAS, Survival, Autoinflammatory diseases, NLRP3, Quality of life, MWS, University of California, San Diego Performance-Based Skills Assessment, Inflammation, Life expectancy, CAPS, Journal of Immunology, Inflammatory bowel disease, Hyperkinesia, Skin, Journal, Patient, NLR, Fatty liver disease, ASO, Weight gain, Fine chemical, Vaccine, Pharmaceutical industry

Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.

Key Points: 
  • Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.
  • CAPS are a spectrum of autoinflammatory diseases caused by activating mutations in the NLRP3 gene.
  • The activity of NLRP3-ASO was tested in an in vivo NOMID disease model; NOMID is the most severe form of CAPS.
  • After systemic ASO treatment, life expectancy was significantly increased, with weight gains and reductions in the severity of skin lesions, showing an overall reduction in systemic inflammation.

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Retrieved on: 
Monday, May 15, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, CITES, Therapy, DC, NK, Perforin-1, Journal of Immunology, T, Walter, Poster, Cytokine, Gene, Pharmaceutical industry, Vaccine, Extractive metallurgy

The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.

Key Points: 
  • The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.
  • “Equillium is developing EQ102 to selectively and synergistically block both IL-15 and IL-21 signaling, without affecting other gamma chain family members.
  • EQ102 is a multi-cytokine inhibitor that selectively blocks IL-15 and IL-21 signaling while preserving signaling of other γc family members.
  • Similarly, in pre-clinical studies, EQ102 has demonstrated the prevention of intestinal tissue damage in a humanized mouse model of gastrointestinal inflammation.

Young Living Announces Mark R. Bartlett as New Executive Vice President of Science and Development

Retrieved on: 
Tuesday, September 13, 2022
John Curtin School of Medical Research, Council for Responsible Nutrition, Australian National University, National, Carbon, Safety, Holm–Bonferroni method, Development, Plaque, Doctor of Philosophy, Chemistry (relationship), Autoimmune disease, Platelet, Cell biology, Young Living, LLC, LEHI, Metastasis, Journal of Immunology, American Association, Industry, Degenerative disease, Photosynthesis, CEO, National university, Science and Development Network, Cell, Friends, Medical research, Biochemistry, Family, Cardiovascular disease, New York Academy of Sciences, LC, Research, Reactive oxygen species, National Cancer Institute, Plant, Council, Health, Tobacco, Management, Pharmaceutical industry, Science, Facebook, Instagram

LEHI, Utah, Sept. 13, 2022 /PRNewswire-PRWeb/ -- Young Living Essential Oils, LLC, the world leader in essential oils and essential oil-infused products, is proud to announce the appointment of Mark R. Bartlett Ph.D. as the company's Executive Vice President of Science and Development.

Key Points: 
  • Young Living Essential Oils, LLC today announced Mark R. Bartlett as its new Executive Vice President of Science and Development.
  • LEHI, Utah, Sept. 13, 2022 /PRNewswire-PRWeb/ -- Young Living Essential Oils, LLC , the world leader in essential oils and essential oil-infused products, is proud to announce the appointment of Mark R. Bartlett Ph.D. as the company's Executive Vice President of Science and Development.
  • Mark Bartlett brings to Young Living a longstanding commitment to health consciousness that is informed by science.
  • "We are thrilled to welcome Mark Bartlett as Young Living's Executive Vice President of Science and Development.

Highly Regarded Cell and Gene Therapy Expert, Dr. Michael Mendicino, Joins NDA Partners as Expert Consultant

Retrieved on: 
Tuesday, September 13, 2022
Science, Partner, Regenerative medicine, Board of directors, CMC, Journal, SCB, Molecular biology, Gene editing, FDA, Center, University, Commissioner of Food and Drugs, Publication, Center for Biologics Evaluation and Research, Science and Technology Select Committee, Tissue engineering, Journal of Immunology, Toxicology, Nature Biotechnology, Program, Telecommunication Technology Committee, Journal of Clinical Investigation, Cell, International Society, General manager, Doctor of Philosophy, ISCT, ARM, Biotechnology, Pharmacokinetics, IND, USP, Medical device, Pharmaceutical industry, Research, Tissue

NDA Partners' General Manager, Eric Fish, announced today that Michael Mendicino, PhD, a highly regarded subject matter expert in cell and gene therapies and related platform technologies, has joined the company as an affiliated Expert Consultant.

Key Points: 
  • NDA Partners' General Manager, Eric Fish, announced today that Michael Mendicino, PhD, a highly regarded subject matter expert in cell and gene therapies and related platform technologies, has joined the company as an affiliated Expert Consultant.
  • WASHINGTON, Sept. 13, 2022 /PRNewswire-PRWeb/ -NDA Partners' General Manager, Eric Fish, announced today that Michael Mendicino, PhD , a highly regarded subject matter expert in cell and gene therapies and related platform technologies, has joined the company as an affiliated Expert Consultant.
  • Dr. Mendicino serves as a Chief Consultant and advisor for companies on CMC/CMC regulatory, regulatory strategy, development strategy, and diligence in the fields of cell and gene therapies, gene editing, regenerative medicine, tissue engineering, and xenotransplantation.
  • Dr. Mendicino is an accomplished leader in cell and gene therapies, and supports numerous professional organizations in the cell and gene therapies area.

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

Retrieved on: 
Monday, August 15, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lupus nephritis, Association, American Association, Risk, Forward-looking statement, Inflammation, Trial of the century, R, Private Securities Litigation Reform Act, SEC, Investment, Degenerative disease, European Society for Primary Immunodeficiencies, Itolizumab, Journal of Immunology, Society, EDGAR, Patient, Alopecia areata, Acquisition, Therapy, Partnership, JAK, Cytokine, G&A, Safety, CD6, Nasdaq, Transplant, Type, MCP, Volunteering, Peptide, Pharmaceutical industry, Vaccine

The second quarter focused largely on the execution of our development programs with itolizumab and our plans to advance the clinical development of our new multi-cytokine inhibitors, EQ101 and EQ102, said Bruce Steel, chief executive officer at Equillium.

Key Points: 
  • The second quarter focused largely on the execution of our development programs with itolizumab and our plans to advance the clinical development of our new multi-cytokine inhibitors, EQ101 and EQ102, said Bruce Steel, chief executive officer at Equillium.
  • The increase was primarily due to greater clinical development expenses, driven by start-up costs related to the Phase 3 EQUATOR study.
  • General and administrative (G&A) expenses for the second quarter of 2022 were $4.1 million, compared with $2.9 million for the same period in 2021.
  • Cash used in operations for the second quarter of 2022 was $11.3 million compared to $12.1 million in the first quarter of 2022.